DICE - DICE Therapeutics, Inc.

DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics.

As of Sep 29, 2026: spot at $24.81, ATM IV 78.6%, net GEX $106.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$2.27B

Beta

0.00

52-Week Range

15.08-47.9

CEO

J. Kevin Judice

Employees

71

IPO Date

Sep 15, 2021

Exchange

NASDAQ

What DICE Looks Like to Options Traders Today

IV rank of 20.8% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($106) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.031) prices calls richer than puts, often reflecting upside speculation or squeeze risk.

What This Page Covers

The DICE overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.